C-X-C Chemokine Receptor Type 4 (CXCR4) and Programmed Death-Ligand 1 (PD-L1) Expression are Prognostic Biomarkers for Papillary Thyroid Carcinoma

被引:0
|
作者
Ding, Ting [1 ]
Song, Qian [1 ]
Xu, Yanjun [2 ]
Liu, Qiya [3 ]
机构
[1] Huanggang Cent Hosp, Dept Endocrinol, Huanggang City 438021, Hubei, Peoples R China
[2] Zhejiang Univ Tradit Chinese Med, Dept Special Inspect Sect, Affiliated Hosp 3, Hangzhou 310014, Zhejiang, Peoples R China
[3] Sha He Hosp Chang Ping Dist Beijing, Dept Gen Med, Beijing 100005, Peoples R China
关键词
CXCR4; PD-L1; Papillary Thyroid Carcinoma; Survival Analysis; CANCER; SURVIVAL; NIVOLUMAB; ANTITUMOR; PATHWAY;
D O I
10.1166/jbt.2022.2987
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Chemokines and immunomodulatory factors involve in tumor development. Papillary thyroid carcinoma (PTC) is considered to start from dendritic cell infiltration and then produce immunomodulatory factors. In this study, CXCR4 and PD-L1 biomarkers were used to explore their prognostic role in PTC survival. Confocal microscopy detected the transfection efficiency in tumor cells. 42 PTC patients and thyroiditis patients (control) were enrolled to measure the expressions of CXCR4 and PD-L1. Multi-factor analysis analyzed the effect of combined CXCR4 and PD-L1 expression on ROC. The two groups had no differences in the baseline characteristics. CTXCR4 and PD-L1 level in PTC patients was significantly higher than control. CXCR4 was lowly expressed in thyroid cancer tissue and PD-L1 was highly expressed in serological samples. Compared with single measurement, the combined detection of CXCR4 and PD-L1 showed more ROC area. In conclusion, reduced CXCR4 and increased PD-L1 levelis found in thyroid cancer and their level might be used IP: 182.75.148.10 On: Thu, 20 Jan 2022 10:55:44 as predictive markers for PTtoCopyright:improve thAmeriancurative Scintificeffect. Publishers
引用
收藏
页码:953 / 957
页数:5
相关论文
共 50 条
  • [1] C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1)
    Wan, Yafeng
    Ge, Ke
    Zhou, Weijiang
    Lu, Jun
    Jia, Changku
    Zhu, Hanzhang
    BIOLOGICAL CHEMISTRY, 2021, 402 (06) : 729 - 737
  • [2] Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma
    Richter, Igor
    Jirasek, Tomas
    Cermakova, Eva
    Bartos, Jiri
    Buchler, Tomas
    Dvorak, Josef
    JOURNAL OF BUON, 2019, 24 (05): : 2155 - 2160
  • [3] Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
    Imanishi, Naoko
    Hirai, Ayako
    Yoneda, Kazue
    Shimajiri, Shohei
    Kuwata, Taiji
    Tashima, Yuko
    Takeuchi, Masahiro
    Iwai, Yoshiko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1563 - 1569
  • [4] PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN PHEOCHROMOCYTOMA
    Hashimoto, Yasuhiro
    Imai, Atsushi
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Koie, Takuya
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2017, 197 (04): : E474 - E474
  • [5] Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
    Zhu, Jun
    Wen, Hao
    Bi, Rui
    Wu, Yong
    Wu, Xiaohua
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (06)
  • [6] Programmed Death-Ligand 1 (PD-L1) Expression in Upper Tract Urothelial Carcinoma
    Skala, Stephanie
    Liu, Tzu-Ying
    Udager, Aaron M.
    Weizer, Alon Z.
    Montgomery, Jeffrey S.
    Palapattu, Ganesh S.
    Siddiqui, Javed
    Cao, Xuhong
    Fields, Kristina
    Abugharib, Ahmed E.
    Soliman, Moaaz
    Hafez, Khaled S.
    Miller, David
    Lee, Cheryl T.
    Alva, Ajjai
    Chinnaiyan, Arul M.
    Morgan, Todd M.
    Spratt, Daniel E.
    Jiang, Hui
    Mehra, Rohit
    MODERN PATHOLOGY, 2017, 30 : 260A - 260A
  • [7] Programmed Death-Ligand 1 (PD-L1) Expression in Upper Tract Urothelial Carcinoma
    Skala, Stephanie
    Liu, Tzu-Ying
    MUdager, Aaron
    Weizei, Alon Z.
    Montgomery, Jeffrey S.
    Palapattu, Ganesh S.
    Siddiqui, Javed
    Cao, Xuhong
    Fields, Kristina
    Abugharib, Ahmed E.
    Soliman, Moaaz
    Hafez, Khaled S.
    Miller, David
    Lee, Cheryl T.
    Alva, Ajjai
    Chinnaiyan, Arul M.
    Morgan, Todd M.
    Sprott, Daniel E.
    Jiang, Hui
    Mehra, Rohit
    LABORATORY INVESTIGATION, 2017, 97 : 260A - 260A
  • [8] Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells
    Brancaccio, Diego
    Diana, Donatella
    Di Maro, Salvatore
    Di Leva, Francesco Saverio
    Tomassi, Stefano
    Fattorusso, Roberto
    Russo, Luigi
    Scala, Stefania
    Trotta, Anna Maria
    Portella, Luigi
    Novellino, Ettore
    Marinelli, Luciana
    Carotenuto, Alfonso
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (07) : 2910 - 2923
  • [9] Programmed death-ligand 1 (PD-L1) expression in pheochromocytoma.
    Hashimoto, Yasuhiro
    Yamamoto, Hayato
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma
    Gulec, Umran Kucukgoz
    Bagir, Emine Kilic
    Paydas, Semra
    Guzel, Ahmet Baris
    Gumurdulu, Derya
    Vardar, Mehmet Ali
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 244 : 51 - 55